Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation

Hallahan, 1995, Spatial and temporal control of gene therapy using ionizing radiation, Nat Med, 1, 786, 10.1038/nm0895-786 Seung, 1995, Genetic radiotherapy overcomes tumor resistance to cytotoxic agents, Cancer Res, 55, 5561 Weichselbaum, 1992, Gene therapy targeted by ionizing radiation, Int J Radiat Oncol Biol Phys, 24, 565, 10.1016/0360-3016(92)91075-X Chmura, 1999, Strategies for enhancing viral-based gene therapy using ionizing radiation, Radiat Oncol Invest, 7, 261, 10.1002/(SICI)1520-6823(1999)7:5<261::AID-ROI1>3.0.CO;2-V Curiel, 1999, Strategies to adapt adenoviral vectors for targeted delivery, Ann N Y Acad Sci, 886, 158, 10.1111/j.1749-6632.1999.tb09409.x Sigal, 2000, Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome, Cancer Res, 60, 6788 Roth, 1999, p53 prognostication: Paradigm or paradox?, Clin Cancer Res, 5, 3345 Roth, 1999, p53 tumor suppressor gene therapy for cancer, Oncology (Hunting), 13, 148 Macleod, 1995, p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage, Genes Dev, 9, 935, 10.1101/gad.9.8.935 Jabbur, 2000, DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and mdm-2 induction in vivo, Oncogene, 19, 6203, 10.1038/sj.onc.1204017 Kearsey, 1995, Does the p53 up-regulated Gadd45 protein have a role in excision repair?, Science, 270, 1004, 10.1126/science.270.5238.1004 Smith, 1994, Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen, Science, 266, 1376, 10.1126/science.7973727 Kastan, 1992, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell, 71, 587, 10.1016/0092-8674(92)90593-2 Szumiel, 1994, Ionizing radiation-induced cell death, Int J Radiat Biol, 66, 329, 10.1080/09553009414551271 Milas, 1994, Relation of apoptosis to cancer therapy, In Vivo, 8, 665 Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 Fan, 1994, p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents, Cancer Res, 54, 5824 Zhang, 1995, Advances in cancer gene therapy, Adv Pharmacol, 32, 289, 10.1016/S1054-3589(08)61016-9 Fujiwara, 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res, 54, 2287 Bristow, 1994, Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated Hras, Oncogene, 9, 1527 Lucke-Huhle, 1994, Alterations in oncogene expression and radiosensitivity in the most frequently used SV40-transformed human skin fibroblasts, Int J Radiat Biol, 65, 665, 10.1080/09553009414550781 Su, 1992, Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and p53 binding domains, Int J Radiat Biol, 62, 461, 10.1080/09553009214552341 Kawabe, 2001, Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts, Int J Radiat Biol, 77, 185, 10.1080/09553000010008540 Cowen, 2000, Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy, Clin Cancer Res, 6, 4402 Weill, 2000, Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection, Chest, 118, 966, 10.1378/chest.118.4.966 Fujiwara, 1999, [A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer], Nippon Geka Gakkai Zasshi, 100, 749 Swisher, 1999, Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer, J Natl Cancer Inst, 91, 763, 10.1093/jnci/91.9.763 Anderson, 1998, Glutathione therapy: From prodrugs to genes, Semin Liver Dis, 18, 415, 10.1055/s-2007-1007174 Zwacka, 1998, Gene therapy for colon cancer, Hematol Oncol Clin North Am, 12, 595, 10.1016/S0889-8588(05)70010-1 Robertson, 1998, Gene therapy for ovarian carcinoma, Semin Oncol, 25, 397 Chung, 1998, Gene therapy for tumors of the central nervous system, Surg Oncol Clin N Am, 7, 589, 10.1016/S1055-3207(18)30262-X Singhal, 1998, Cancer chemotherapy using suicide genes, Surg Oncol Clin N Am, 7, 505, 10.1016/S1055-3207(18)30258-8 Dachs, 1997, Targeting gene therapy to cancer: A review, Oncol Res, 9, 313 Martin, 1996, Direct cell killing by suicide genes, Cancer Metastasis Rev, 15, 301, 10.1007/BF00046344 Moolten, 1990, Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors, J Natl Cancer Inst, 82, 297, 10.1093/jnci/82.4.297 Ezzeddine, 1991, Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene, New Biol, 3, 608 Niranjan, 2000, Effective treatment of experimental glioblastoma by HSV vectormediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration, Mol Ther, 2, 114, 10.1006/mthe.2000.0101 Moriuchi, 2000, HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma, Gene Ther, 7, 1483, 10.1038/sj.gt.3301265 Kim, 1995, Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents, Int J Radiat Oncol Biol Phys, 33, 861, 10.1016/0360-3016(95)00134-9 Kim, 1994, Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene, Cancer Res, 54, 6053 Andersen, 1989, Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K 12. Involvement of the glnLG and purR genes in the regulation of codA expression, Arch Microbiol, 152, 115, 10.1007/BF00456087 Mullen, 1994, Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor, Cancer Res, 54, 1503 Mullen, 1992, Transfer of the bacterial gene for cytosinc deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system, Proc Natl Acad Sci USA, 89, 33, 10.1073/pnas.89.1.33 Piccart, 1988, Six-year results of a multimodality treatment strategy for locally advanced breast cancer, Cancer, 62, 2501, 10.1002/1097-0142(19881215)62:12<2501::AID-CNCR2820621209>3.0.CO;2-5 Moertel, 1969, Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer, Lancet, 2, 865, 10.1016/S0140-6736(69)92326-5 Moertel, 1981, Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group, Cancer, 48, 1705, 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4 O'Connell, 1994, Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery, N Engl J Med, 331, 502, 10.1056/NEJM199408253310803 Bruso, 1990, Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells, Int J Radiat Oncol Biol Phys, 19, 1411, 10.1016/0360-3016(90)90352-K Parker, 1990, Metabolism and mechanism of action of 5-fluorouracil, Pharmacol Ther, 48, 381, 10.1016/0163-7258(90)90056-8 Weckbecker, 1991, Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators, Pharmacol Ther, 50, 367, 10.1016/0163-7258(91)90051-M Khil, 1996, Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene, Clin Cancer Res, 2, 53 Pederson, 1997, Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo, Cancer Res, 57, 4325 Hanna, 1997, Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts, Cancer Res, 57, 4205 Rogulski, 1997, Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity, Hum Gene Ther, 8, 73, 10.1089/hum.1997.8.1-73 Andrade-Rozental, 2000, Gap junctions: The “kiss of death” and the “kiss of life”, Brain Res Brain Res Rev, 32, 308, 10.1016/S0165-0173(99)00099-5 Tanaka, 2001, Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro, Int J Cancer, 91, 538, 10.1002/1097-0215(200002)9999:9999<::AID-IJC1080>3.0.CO;2-Z Wildner, 1999, In situ use of suicide genes for therapy of brain tumours, Ann Med, 31, 421, 10.3109/07853899908998799 Kun, 1995, Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors, Hum Gene Ther, 6, 1231, 10.1089/hum.1995.6.9-1231 Rainov, 2000, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, Hum Gene Ther, 11, 2389, 10.1089/104303400750038499 Schwarzenberger, 1998, The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study, Hum Gene Ther, 9, 2641, 10.1089/hum.1998.9.17-2641 Schwarzenberger, 1998, Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana, J La State Med Soc, 150, 168 Eck, 1996, Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial, Hum Gene Ther, 7, 1465, 10.1089/hum.1996.7.12-1465 Klatzmann, 1998, A phase 1/11 study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma, Hum Gene Ther, 9, 2595, 10.1089/hum.1998.9.17-2595 Klatzmann, 1998, A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma, Hum Gene Ther, 9, 2585, 10.1089/hum.1998.9.17-2585 Ram, 1997, Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells, Nat Med, 3, 1354, 10.1038/nm1297-1354 Dasika, 1999, DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis, Oncogene, 18, 7883, 10.1038/sj.onc.1203283 Weichselbaum, 1994, Radiation induction of immediate early genes: Effectors of the radiation-stress response, Int J Radiat Oncol Biol Phys, 30, 229, 10.1016/0360-3016(94)90539-8 Sherman, 1990, Ionizing radiation regulates expression of the c-jun protooncogene, Proc Natl Acad Sci USA, 87, 5663, 10.1073/pnas.87.15.5663 Hallahan, 1991, Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines, Int J Radiat Oncol Biol Phys, 21, 1677, 10.1016/0360-3016(91)90352-5 Hallahan, 1991, Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN, Proc Natl Acad Sci USA, 88, 2156, 10.1073/pnas.88.6.2156 Datta, 1992, Ionizing radiation activates transcription of the EGR1 gene via CArG elements, Proc Natl Acad Sci USA, 89, 10149, 10.1073/pnas.89.21.10149 Datta, 1993, Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation, Proc Natl Acad Sci USA, 90, 2419, 10.1073/pnas.90.6.2419 Sersa, 1988, Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy, Int J Cancer, 42, 129, 10.1002/ijc.2910420124 Old, 1985, Tumor necrosis factor (TNF), Science, 230, 630, 10.1126/science.2413547 Vokes, 1992, The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines, Oncology, 49, 454, 10.1159/000227092 Mauceri, 1997, Increased injection number enhances adenoviral genetic radiotherapy, Radiat Oncol Invest, 5, 220, 10.1002/(SICI)1520-6823(1997)5:5<220::AID-ROI2>3.0.CO;2-# Staba, 1998, Adcnoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft, Gene Ther, 5, 293, 10.1038/sj.gt.3300594 Chung, 1998, Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer, Cancer Gene Ther, 5, 344 Bischoff, 1996, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science, 274, 373, 10.1126/science.274.5286.373 Heise, 1997, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents, Nat Med, 3, 639, 10.1038/nm0697-639 Kirn, 1998, ONYX-015: Clinical data are encouraging, Nat Med, 4, 1341, 10.1038/3902 Hall, 1998, p53-dependent cell death/apoptosis is required for a productive adenovirus infection, Nat Med, 4, 1068, 10.1038/2057 Goodrum, 1998, p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection, J Virol, 72, 9479, 10.1128/JVI.72.12.9479-9490.1998 Rogulski, 2000, In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy, Cancer Res, 60, 1193 Khuri, 2000, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil i in patients with recurrent head and neck cancer, Nat Med, 6, 879, 10.1038/78638 Nemunaitis, 2000, Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial, Cancer Res, 60, 6359 Nemunaitis, 2001, Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J Clin Oncol, 19, 289, 10.1200/JCO.2001.19.2.289 Martuza, 1991, Experimental therapy of human glioma by means of a genetically engineered virus mutant, Science, 252, 854, 10.1126/science.1851332 Markert, 2000, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, Gene Ther, 7, 867, 10.1038/sj.gt.3301205 Markert, 2000, Genetically engineered HSV in the treatment of glioma: A review, Rev Med Virol, 10, 17, 10.1002/(SICI)1099-1654(200001/02)10:1<17::AID-RMV258>3.0.CO;2-G Todo, 2000, Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus, Mol Ther, 2, 588, 10.1006/mthe.2000.0200 Advani, 1998, Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors, Gene Ther, 5, 160, 10.1038/sj.gt.3300546 Bradley, 1999, Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus, Clin Cancer Res, 5, 1517 Khodarev, 1999, Accumulation of specific RNAs encoding transcriptional factors and stress response proteins against a background of severe depletion of cellular RNAs in cells infected with herpes simplex virus 1, Proc Natl Acad Sci USA, 96, 12062, 10.1073/pnas.96.21.12062 Weichselbaum, 1994, Radiation induction of immediate early genes: effectors of the radiation-stress response, Int J Radiat Oncol Biol Phys, 30, 229, 10.1016/0360-3016(94)90539-8